ArticleThorax2011
Emergence of parapneumonic empyema in the USA.
Article in Thorax, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06727578 (A Pilot Assessment of the Safety and Efficacy of Pleural Irrigation for Retained Pleural Infection Using a Novel Irrigation Device), which is not on this map. Cited by 107 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Assessment of the Safety and Efficacy of Pleural Irrigation for Retained Pleural Infection Using a Novel Irrigation Device
Who cites it
107 citing papers in PubMed, 3 syntheses or guidelines pooled it, 286 citations in OpenAlex.
- Outcomes of intrapleural fibrinolytic and deoxyribonuclease therapy in pleural infection: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2026Pooled it
- Intra-pleural fibrinolytic therapy versus placebo, or a different fibrinolytic agent, in the treatment of adult parapneumonic effusions and empyema.The Cochrane database of systematic reviews · 2019Pooled it
- A systematic review of comorbidities and outcomes of adult patients with pleural infection.The European respiratory journal · 2019Pooled it
- Minimally invasive intrathoracic negative-pressure therapy and flexible thoracoscopy (FlexVATS) for patients with pleural empyema.Scientific reports · 2023Trial
- Effect of Intrapleural Fibrinolytic Therapy vs Surgery for Complicated Pleural Infections: A Randomized Clinical Trial.JAMA network open · 2023Trial
- Biological effect of tissue plasminogen activator (t-PA) and DNase intrapleural delivery in pleural infection patients.BMJ open respiratory research · 2019Trial
- Nonsteroidal Anti-Inflammatory Drug without Antibiotics for Acute Viral Infection Increases the Empyema Risk in Children: A Matched Case-Control Study.The Journal of pediatrics · 2016Trial
- Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment.European journal of pediatrics · 2014Trial
- Article
- Difference in clinical characteristics and outcomes between hospital-acquired and community-acquired pleural infection.MedScience · 2026Article
- Cardiovascular complications after pleural infection: incidences, risk factors, and prognostic relevance.BMC cardiovascular disorders · 2026Article
- Managing pleural infections: a nationwide survey of respiratory physicians in Singapore.BMJ open respiratory research · 2026Article
- Bacteriology and clinical outcomes of pleural infections in Singapore: an 8-year retrospective observational study.Journal of thoracic disease · 2026Article
- Review
- Thoracic Extension of an Odontogenic Deep Neck Space Infection: A Case of Carbapenem-ResistantInfection and drug resistance · 2026Article
- What is new in pleural infections?Breathe (Sheffield, England) · 2026Review
- Article
- No culture? No problem: Clinical utility and pitfalls of non-culture diagnostics for pneumococcal parapneumonic effusions.Frontiers in medicine · 2026Review
- Global point prevalence study to determine the variations in aetiology, management and outcomes of pleural infection: a protocol for the international multicentre study of pleural infection (the INTERMITTENT Study).BMJ open respiratory research · 2025Article
- Italian multicentre study on the management of pLeural infection and empyema: IMPLE study.Respiratory research · 2025Observational
47 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundAlthough recent reports suggest that the incidence of parapneumonic empyema has increased in several regions of the USA, national trends in disease burden are unknown. National trends in the incidence of parapneumonic empyema hospitalisations and changes in empyema by associated pathogens were examined.
methodsNational hospitalisation data (1996-2008) were analysed and rates estimated using census estimates as denominators. Incidence rate ratios (IRR) compared 2008 with 1996 rates. Discharge diagnosis codes were used to characterise pathogens associated with empyema hospitalisations.
resultsOverall, national parapneumonic empyema-related hospitalisation rates increased from 3.04 per 100,000 in 1996 to 5.98 per 100,000 in 2008, a 2.0-fold increase (95% CI 1.8 to 2.1). The increases were observed among children (IRR 1.9 (95% CI 1.4 to 2.7)) and adults aged 18-39, 40-64 and ≥65 years (IRR 1.8 (95% CI 1.5 to 2.1), 2.0 (95% CI 1.6 to 3.1) and 1.7 (95% CI 1.5 to 2.0), respectively). Overall, pneumococcal empyema rates remained relatively stable in all age groups whereas streptococcal- (non-pneumococcal) and staphylococcal-related empyema rates increased 1.9-fold and 3.3-fold, respectively, with consistent increases across age groups. The overall in-hospital case fatality ratio for parapneumonic empyema-related hospitalisations was 8.0% (95% CI 6.4% to 9.5%) in 1996 and 7.2% (95% CI 6.3% to 8.1%) in 2008 (p=0.395). Of the empyemas where study pathogens were listed (37.6%), staphylococcal-related empyema had the largest absolute increases across age groups and was associated with longer hospital stay and higher in-hospital mortality than other empyemas.
conclusionsAlthough parapneumonic empyema-related hospitalisations remained relatively rare, they increased substantially during the study period. A number of pathogens, especially staphylococcus, contributed to this increase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.